ProQR Therapeutics NV
NASDAQ:PRQR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.35
4.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ProQR Therapeutics NV
ProQR Therapeutics NV
Operating Expenses
ProQR Therapeutics NV
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Expenses
-€48m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Expenses
-$269.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-34%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Expenses
-$196.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-15%
|
|
|
argenx SE
XBRU:ARGX
|
Operating Expenses
-$2.2B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-83%
|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Expenses
-$266.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Operating Expenses
-$46.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ProQR Therapeutics NV
Glance View
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
See Also
What is ProQR Therapeutics NV's Operating Expenses?
Operating Expenses
-48m
EUR
Based on the financial report for Sep 30, 2024, ProQR Therapeutics NV's Operating Expenses amounts to -48m EUR.
What is ProQR Therapeutics NV's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
3%
Over the last year, the Operating Expenses growth was -13%. The average annual Operating Expenses growth rates for ProQR Therapeutics NV have been 4% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
